Member Info for Soupdragon78

Dunno, I'd say sentiment was lower when they were placing at 0.05p to stay alive.

No presentations, it was a networking and mentoring day. Dans done it before.

Plus it was on Wednesday so no need to sit down.

Have a solero and enjoy the sun.

Thanks for letting us know you've sold Comical Ali, although you didn't need a 500 word post to tell us really.

Laters....

They updated the market 3 weeks ago.

People need to manage their own expectations rather than the company constantly holding their hand.

Anyway it’s good to see Comical Ali finally realise that Ringlet has nothing to do with NFX.

Revisionist history from someone who said.

“Fibroinflammatory resolution to restore homeostasis and cure disease (NXP002 anyone!) - COMING SOON"

Coincidence, I don't think so (famous last words).”

Makes more sense to buy and sell 12.5m for a small profit by the look of it

Back in 2022 Cizzle acquired a stake in a therapy called AZ1656 for the treatment of inflammatory pulmonary diseases.

AZ1656 is being developed by Conduit Pharma who operate as a virtual pharma co.

Conduit Pharma was set up by Dave Tapolczay who was founder of Nuformix and Chairman until he left after the debacle of the NXP001 China deal.

Furthermore Conduit Pharma recruited Joanne Holland who developed all of the Nuformix therapies 001, 002 & 004 and her name is on all the patents as inventor.

Don't tell Comical Ali about the links between Cizzle and NFX, he'll then have to pivot to them buying NXP002.

Comical Ali, I would suggest you speak to Dan.

Keeping the main market listing costs them around £300k p.a. for the listing and fees etc. So they have circa £700k which is for the pre-clinical works, so it will last as long as it lasts, they don't have a consistent monthly spend as its spent by project work rather than evenly spaced.

Anyone seen Comical Ali?

Top research Ali, a confirmation statement, a change of address and a share allocation from January. Lol!

Even Princess Anne is closer to the reality here than you.

Thanks bubbleshoot, also highlights the move toward combination therapies which is where NxP002 is being positioned.

BI is always a possibility especially now they have a therapy in the market and the Fibroneer trials showed it still causes side effect issues. The benefit to them is to have an oral treatment to slow progressions and then and inhaled treatment to reduce scarring (and in the ideal situation potentially reverse the damage)

Wait till you hear about Dan's skateboarding company. Tony Hawks is personally going to test out NXP002!

Bubbleshoot, the Haisco deal is not comparable as their therapy is at Phase 2 clinical trials, hence the increased up front payment.

The closest comparison is AZ's agreement with RedX at preclinical stage with up to $17m upfront.

Secondly, Ringlet has nothing to do with NFX, they're looking at something completely different.

Nbili, the Orphan Designation 7 year started when the product is available on the market otherwise it would be pointless.

Anyway Comical Ali is telling us we are doing a deal with Ringlet and their VC and not a major pharma now so we need to forget the partners that we've been in discussion with.

Lol.

Thats true Ali. Even GCSE level chemistry would help you understand the difference between Ringlet and NFX.